1,092 results
Search Results
2. Vascularized composite allotransplantation – a Council of Europe position paper.
- Author
-
Thuong, Marie, Petruzzo, Palmina, Landin, Luis, Mahillo, Beatriz, Kay, Simon, Testelin, Sylvie, Jablecki, Jerzy, Laouabdia‐Sellami, Karim, Lopez‐Fraga, Marta, and Dominguez‐Gil, Beatriz
- Subjects
- *
ORGAN donation , *ARM , *CLINICAL trials , *HEALTH , *TRANSPLANTATION of organs, tissues, etc. , *FACIAL transplantation - Abstract
Summary: After more than 120 hand‐upper extremity and 37 face transplant procedures performed worldwide, vascularized composite allotransplantation (VCA) now falls under the scope of organ transplant legislation in Europe and the United States. While in the USA, VCA has been considered as standard care since 2014, VCA in Europe is still performed through clinical research trials, except in United Kingdom. However, after two decades of favourable experience with upper extremity transplantation (UET), professionals in Europe are proposing hand allotransplantation as "controlled standard" care, as opposed to face transplantation (FT), which is still a challenging activity. The European Committee on Organ Transplantation (CD‐P‐TO) has elaborated a position paper to provide recommendations concerning regulatory aspects for UET and FT. It is aimed at Health Authorities in charge of the oversight – and coordination – of organ donation and transplantation, and at professional groups to help them manage such complex and costly programs dedicated to properly selected patients. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
3. Digitalizing the Clinical Research Informed Consent Process: Assessing the Participant Experience in Comparison With Traditional Paper-Based Methods.
- Author
-
Buckley, Michael T., O'Shea, Molly R., Kundu, Sangeeta, Lipitz-Snyderman, Allison, Kuperman, Gilad, Shah, Suken, Iasonos, Alexia, Houston, Collette, Terzulli, Stephanie L., Lengfellner, Joseph M., and Sabbatini, Paul
- Subjects
SELF advocacy ,HUMAN research subjects ,CLINICAL trials ,ACADEMIC medical centers ,CLINICAL medicine research ,QUANTITATIVE research ,INFORMED consent (Medical law) ,EXPERIENCE ,COMPARATIVE studies ,SURVEYS ,QUALITATIVE research ,SOCIOECONOMIC factors ,QUALITY assurance ,SCALE analysis (Psychology) ,RESEARCH funding ,ELIGIBILITY (Social aspects) ,CHI-squared test ,DESCRIPTIVE statistics ,ELECTRONIC health records ,MEDICAL informatics ,SOCIODEMOGRAPHIC factors ,COVID-19 pandemic ,TELEMEDICINE - Abstract
PURPOSE Consent processes are critical for clinical care and research and may benefit from incorporating digital strategies. We compared an electronic informed consent (eIC) option to paper consent across four outcomes: (1) technology burden, (2) protocol comprehension, (3) participant agency (ability to self-advocate), and (4) completion of required document fields. METHODS We assessed participant experience with eIC processes compared with traditional paper-based consenting using surveys and compared completeness of required fields, over 3 years (2019-2021). Participants who consented to a clinical trial at a large academic cancer center via paper or eIC were invited to either pre-COVID-19 pandemic survey 1 (technology burden) or intrapandemic survey 2 (comprehension and agency). Consent document completeness was assessed via electronic health records. RESULTS On survey 1, 83% of participants (n = 777) indicated eIC was easy or very easy to use; discomfort with technology overall was not correlated with discomfort using eIC. For survey 2, eIC (n = 262) and paper consenters (n = 193) had similar comprehension scores. All participants responded favorably to at least five of six agency statements; however, eIC generated a higher proportion of positive free-text comments (P < .05), with themes such as thoroughness of the discussion and consenter professionalism. eIC use yielded no completeness errors across 235 consents versus 6.4% for paper (P < .001). CONCLUSION Our findings suggest that eIC when compared with paper (1) did not increase technology burden, (2) supported comparable comprehension, (3) upheld key elements of participant agency, and (4) increased completion of mandatory consent fields. The results support a broader call for organizations to offer eIC for clinical research discussions to enhance the overall participant experience and increase the completeness of the consent process. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. An evaluation of assumptions underlying respondent‐driven sampling and the social contexts of sexual and gender minority youth participating in HIV clinical trials in the United States.
- Author
-
Wirtz, Andrea L., Iyer, Jessica R., Brooks, Durryle, Hailey‐Fair, Kimberly, Galai, Noya, Beyrer, Chris, Celentano, David, and Arrington‐Sanders, Renata
- Subjects
SEXUAL minorities ,SOCIAL context ,CLINICAL trials ,HIV ,ELECTRONIC paper - Abstract
Introduction: Respondent‐driven sampling (RDS) has been an effective sampling strategy for HIV research in many settings, but has had limited success among some youth in the United States. We evaluated a modified RDS approach for sampling Black and Latinx sexual and gender minority youth (BLSGMY) and explored how lived experiences and social contexts of BLSGMY youth may impact traditional RDS assumptions. Methods: RDS was implemented in three US cities, Baltimore, Philadelphia and Washington DC, to engage BLSGMY aged 15 to 24 years in HIV prevention or care intervention trials. RDS was modified to include targeted seed recruitment from venues, Internet and health clinics, and provided options for electronic or paper coupons. Qualitative interviews were conducted among a sub‐sample of RDS participants to explore their experiences with RDS. Interviews were coded using RDS assumptions as an analytic framework. Results: Between August 2017 and October 2019, 405 participants were enrolled, 1670 coupons were distributed, with 133 returned, yielding a 0.079 return rate. The maximum recruitment depth was four waves among seeds that propagated. Self‐reported median network size was 5 (IQR 2 to 10) and reduced to 3 (IQR 1 to 5) when asked how many peers were seen in the past 30 days. Qualitative interviews (n = 27) revealed that small social networks, peer trust and targeted referral of peers with certain characteristics challenged network, random recruitment, and reciprocity assumptions of RDS. HIV stigma and research hesitancy were barriers to participation and peer referral. Other situational factors, such as phone ownership and access to reliable transportation, reportedly created challenges for referred peers to participate in research. Conclusions: Small social networks and varying relationships with peers among BLSGMY challenge assumptions that underlie traditional RDS. Modified RDS approaches, including those that incorporate social media, may support recruitment for community‐based research but may challenge assumptions of reciprocal relationships. Research hesitancy and situational barriers are relevant and must be addressed across any sampling method and study design that includes BLSGMY in the United States. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
5. Principles Supporting Dynamic Clinical Care Teams: An American College of Physicians Position Paper.
- Author
-
Doherty, Robert B. and Crowley, Ryan A.
- Subjects
- *
MEDICAL care , *PHYSICIANS , *CLINICAL trials , *HEALTH policy - Abstract
The U.S. health care system is undergoing a shift from individual clinical practice toward team-based care. This move toward team-based care requires fresh thinking about clinical leadership and responsibilities to ensure that the unique skills of each clinician are used to provide the best care for the patient as the patient's needs dictate, while the team as a whole must work together to ensure that all aspects of a patient's care are coordinated for the benefit of the patient. In this position paper, the American College of Physicians offers principles, definitions, and examples to dissolve barriers that prevent movement toward dynamic clinical care teams. These principles offer a framework for an evolving, updated approach to health care delivery, providing policy guidance that can be useful to clinical teams in organizing the care processes and clinician responsibilities consistent with professionalism. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
6. Computerized Neuropsychological Assessment Devices: Joint Position Paper of the American Academy of Clinical Neuropsychology and the National Academy of Neuropsychology.
- Author
-
Bauer, Russell M., Iverson, Grant L., Cernich, Alison N., Binder, Laurence M., Ruff, Ronald M., and Naugle, Richard I.
- Subjects
- *
NEUROPSYCHOLOGICAL tests , *COMPUTERIZED instruments , *CLINICAL trials , *DATA security , *MEDICAL needs assessment - Abstract
This joint position paper of the American Academy of Clinical Neuropsychology and the National Academy of Neuropsychology sets forth our position on appropriate standards and conventions for computerized neuropsychological assessment devices (CNADs). In this paper, we first define CNADs and distinguish them from examiner-administered neuropsychological instruments. We then set forth position statements on eight key issues relevant to the development and use of CNADs in the healthcare setting. These statements address (a) device marketing and performance claims made by developers of CNADs; (b) issues involved in appropriate end-users for administration and interpretation of CNADs; (c) technical (hardware/software/firmware) issues; (d) privacy, data security, identity verification, and testing environment; (e) psychometric development issues, especially reliability and validity; (f) cultural, experiential, and disability factors affecting examinee interaction with CNADs; (g) use of computerized testing and reporting services; and (h) the need for checks on response validity and effort in the CNAD environment. This paper is intended to provide guidance for test developers and users of CNADs that will promote accurate and appropriate use of computerized tests in a way that maximizes clinical utility and minimizes risks of misuse. The positions taken in this paper are put forth with an eye toward balancing the need to make validated CNADs accessible to otherwise underserved patients with the need to ensure that such tests are developed and utilized competently, appropriately, and with due concern for patient welfare and quality of care. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
7. Recommendations on Evidence Needed to Support Measurement Equivalence between Electronic and Paper-Based Patient-Reported Outcome (PRO) Measures: ISPOR ePRO Good Research Practices Task Force Report.
- Author
-
Coons, Stephen Joel, Gwaltney, Chad J., Hays, Ron D., Lundy, J. Jason, Sloan, Jeff A., Revicki, Dennis A., Lenderking, William R., Cella, David, and Basch, Ethan
- Subjects
- *
HEALTH outcome assessment , *CLINICAL trials , *CLINICAL drug trials , *MEDICAL care - Abstract
Background: Patient-reported outcomes (PROs) are the consequences of disease and/or its treatment as reported by the patient. The importance of PRO measures in clinical trials for new drugs, biological agents, and devices was underscored by the release of the US Food and Drug Administration's draft guidance for industry titled “Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims.” The intent of the guidance was to describe how the FDA will evaluate the appropriateness and adequacy of PRO measures used as effectiveness end points in clinical trials... [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
8. Position Paper: Recommended Design Features of Future Clinical Trials of Antibacterial Agents for Community-Acquired Pneumonia.
- Subjects
- *
CLINICAL trials , *CLINICAL medicine research , *COMMUNITY-acquired pneumonia , *LUNG diseases , *ANTIBIOTICS , *ANTIBACTERIAL agents , *HEALTH outcome assessment , *MORTALITY - Abstract
The article presents the recommended design features of future clinical trials of antibacterial agents for community-acquired pneumonia (CAP). The efficaciousness of new antibiotics for the treatment of CAP has been assessed and compared with that of established antibiotics in noninferiority clinical trials. But the U.S. Food and Drug Administration is reassessing the appropriateness of a noninferiority trial design for CAP. Based on the pertinent data, there is a definitive and substantial treatment effect of antibiotic therapy for CAP. The evidence supporting a treatment effect of antibiotics includes higher mortality rates among patients with CAP, immediate decline in the mortality due to CAP, higher rates of treatment failure among patients infected with organisms and many others.
- Published
- 2008
- Full Text
- View/download PDF
9. From Paper to Electronic the FDA Way.
- Author
-
Hulihan, Earl W. and Siconolfi, Richard M.
- Subjects
- *
HEALTH policy , *MEDICARE , *PUBLIC health , *CLINICAL trials , *GOVERNMENT policy - Abstract
The article focuses on the guidelines released by the Food & Drug Administration (FDA), which demonstrates the flexibility and willingness of the department to engage regulated entities in the U.S. It provides specific definitions for source documentation and direct data entry, and recommendations on how to use computerized systems in clinical investigations. It also includes advice for clinical sites, analytical laboratories, and central laboratories. INSET: FDA Regulations vs Guidances.
- Published
- 2008
10. Using Facebook ads with traditional paper mailings to recruit adolescent girls for a clinical trial.
- Author
-
Schwinn, Traci, Hopkins, Jessica, Schinke, Steven P, and Liu, Xiang
- Subjects
- *
PSYCHOLOGY of teenage girls , *DRUG abuse prevention , *CLINICAL trials , *INFORMATION theory , *ADVERTISING , *INTERNET , *POSTAL service , *RESEARCH funding , *SOCIAL networks , *HUMAN research subjects , *PATIENT selection - Abstract
Introduction: Clinical trials require sufficient samples recruited within limited time and budget constraints. Trials with minors are additionally burdened by the requirement for youth assent and parental permission. This paper details the use of Facebook ads and traditional paper mailings to enroll 797 adolescent girls for a longitudinal, web-based, drug abuse prevention trial. Data on sample representativeness and retention are also provided.Methods: Facebook ads appeared on the pages of females aged 13 or 14years who reside in the U.S. Ads linked girls to a recruitment website. Girls who wanted more information submitted contact information and were mailed information packets to their homes containing, among other things, youth assent and parent permission forms. Returned forms were verified for accuracy and validity.Results: The Facebook ad campaign reached 2,267,848 girls and had a unique click-through rate of 3.0%. The campaign cost $41,202.37 with an average cost of $51.70 per enrolled girl. Information packets were mailed to 1,873 girls. Approximately one-half of girls returned the forms, and 797 girls were enrolled. The Facebook campaign's success varied by ad type, month, and day of the week. Baseline data revealed comparability to national data on demographic and substance use variables.Conclusions: Results suggest that Facebook ads provide a useful initial point of access to unparalleled numbers of adolescents. Clinical trials may benefit from a two-fold recruitment strategy that uses online ads to attract interested adolescents followed by traditional recruitment methods to communicate detailed information to adolescents and parents. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
11. Cost-effectiveness of talazoparib for patients with germline BRCA1/2 mutated HER2-negative advanced breast cancer in China and the US.
- Author
-
Pan, Junjie, Ren, Ning, Ren, Lanqi, Yang, YiBei, and Xu, Qiaoping
- Subjects
METASTATIC breast cancer ,BRCA genes ,BREAST ,CLINICAL trials ,COST effectiveness ,PROGRESSION-free survival ,GERM cells ,AGRICULTURAL extension work - Abstract
Breast cancer is one of the tumors with the highest prevalence rate among women in the world, and its BRCA1/2 gene is a common mutation site. Talazoparib, as a targeted PARP inhibitor, can effectively control the occurrence and development of breast cancer with BRCA1/2 gene mutation, and play a therapeutic role. Based on the findings from the Phase III EMBRACE trial (NCT01945775 clinical trial), our analysis reveals that the talazoparib group demonstrated a significant extension in progression-free survival, along with improved response markers and patient-reported outcomes when compared to conventional therapies. This study aims to assess the cost-effectiveness of talazoparib for treating advanced breast cancer with germline BRCA1/2 mutations and HER2 negativity, considering the perspectives of health services in China and the United States. The results obtained will serve as a valuable reference for promoting rational drug utilization and enhancing medical resource efficiency. To evaluate the cost-effectiveness of Talazoparib more scientifically and provide clinicians with chemotherapy options, this paper developed a Markov model based on the EMBRACA clinical trial (clinical Trails.gov No., NCT01945775) to simulate the survival events of breast cancer patients in the Talazoparib group and the standard treatment group. The state transition probability and clinical data of breast cancer patients during treatment were extracted from the phase III EMBRACA clinical trial. The cost data generated during the treatment process comes from local hospital pricing, other references, and expert consultation. This article uses US dollars to calculate the treatment cost and incremental cost-effectiveness ratio. Health outcomes are expressed in Quality Adjusted Life Years (QALYs). In addition, Outcomes were measured in quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratio, which robustness was evaluated by deterministic and probabilistic sensitivity analyses. This article establishes a Markov model for single-item sensitivity analysis. The results show that the economic benefits of using Talazoparib as a new treatment strategy in both China and the United States are higher than other drugs, and it is cost-effective. Compared to the control group, the incremental cost incurred by the Talazoparib treatment group in China was $2484.48/QALY, with an incremental QALY of 1.5. However, Talazoparib in the United States holds a dominant position, saving costs of $10,223.43 and increasing QALYs by 1.5. The clinical treatment effect of Talazoparib group in BRCA1/2 mutant advanced breast cancer patients is better than that of the standard treatment group, and the progression free survival period is significantly prolonged. From the perspective of medical and health services in China and the United States, the Talazoparib group is more economical than the standard treatment group in treating patients with BRCA1/2 mutant advanced breast cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
12. A bibliometric analysis on the health behaviors related to mild cognitive impairment.
- Author
-
Liping Xiao, Chunyi Zhou, Shibo Zhang, and Yuncui Wang
- Subjects
DEMENTIA prevention ,SERIAL publications ,LIFESTYLES ,MILD cognitive impairment ,CLUSTER analysis (Statistics) ,EXERCISE ,INTERPROFESSIONAL relations ,RESEARCH funding ,CLINICAL trials ,CITATION analysis ,DESCRIPTIVE statistics ,AUTHORSHIP ,THEMATIC analysis ,BIBLIOMETRICS ,HEALTH behavior ,AGING ,DATA analysis software ,BEHAVIORAL research ,DIET ,PREVENTIVE health services ,BIOMARKERS ,COGNITION ,DISEASE risk factors ,MIDDLE age ,OLD age - Abstract
Background: Mild cognitive impairment (MCI) is commonly defined as a transitional subclinical state between normal aging and dementia. A growing body of research indicates that health behaviors may play a protective role against cognitive decline and could potentially slow down the progression from MCI to dementia. The aim of this study is to conduct a bibliometric analysis of literature focusing on health behaviors and MCI to summarize the factors and evidence regarding the influence of health behaviors on MCI. Methods: The study performed a bibliometric analysis by retrieving publications from the Science Citation Index and Social Sciences Citation Index subdatabases within the Web of Science Core Collection. Utilizing VOSviewer and CiteSpace software, a total of 2,843 eligible articles underwent co-citation, cokeywords, and clustering analyses. This methodology aimed to investigate the current status, trends, major research questions, and potential future directions within the research domain. Results: The bibliometric analysis indicates that research on healthy behaviors in individuals with MCI originated in 2002 and experienced rapid growth in 2014, reflecting the increasing global interest in this area. The United States emerged as the primary contributor, accounting for more than one-third of the total scientific output with 982 articles. Journals that published the most articles on MCI-related health behaviors included "Journal of Alzheimer's Disease," "Neurobiology of Aging," "Frontiers in Aging Neuroscience," and other geriatricsrelated journals. High-impact papers identified by VOSviewer predominantly cover concepts related to MCI, such as diagnostic criteria, assessment, and multifactorial interventions. Co-occurrence keyword analysis highlights five research hotspots in health behavior associated with MCI: exercise, diet, risk factors and preventive measures for dementia, cognitive decline-related biomarkers, and clinical trials. Conclusion: This study provides a comprehensive review of literature on health behavior in individuals with MCI, emphasizing influential documents and journals. It outlines research trends and key focal points, offering valuable insights for researchers to comprehend significant contributions and steer future studies. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
13. Analysis of a Collaborative Research Network of Botulinum Toxin Clinical Trials.
- Author
-
Jiseon Jang, Hyeongjin Ahn, and Eunil Park
- Subjects
COOPERATIVE research ,BOTULINUM toxin ,CLINICAL trials ,DATABASES - Abstract
Recently, pharmaceutical companies have been striving to occupy a greater percentage of the global market with clinical research actively being conducted through mutual collaboration networks. In particular, the international Botulinum toxin (BT) market is characterized by intensifying competition. The majority of BT research has been conducted in the United States and Europe, whilst various countries have started their regional research through international collaboration networks. With this trend, this study aimed to examine the current collaboration trend and network of clinical trial research in the field of BT by employing both bibliometric and collaboration network analyses with one of the global academic and research databases. Based on the collaboration network, which is organized by 8,296 articles and 10,298 institutes, four centrality measures successfully present several international and regional clinical BT research leading institutes. Moreover, there are some hidden active institutes in this area, which are not highlighted in this paper's bibliometric analysis. This study contributes to improving the understanding of clinical trials in BTresearch, a relevant medical topic. Moreover, collaboration network analysis is one of the most valuable approaches of examining the international and regional clinical research. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
14. Global trends in tumor microenvironment-related research on tumor vaccine: a review and bibliometric analysis.
- Author
-
Ying Liu, Sixin Li, Lu Chen, Lin Lin, Caijuan Xu, Huiwen Qiu, Xinyu Li, Hui Cao, and Kun Liu
- Subjects
CANCER vaccines ,BIBLIOMETRICS ,CLINICAL trials ,TUMOR microenvironment ,VACCINE effectiveness - Abstract
Background: Tumor vaccines have become crucial in cancer immunotherapy, but, only a limited number of phase III clinical trials have demonstrated clinical efficacy. The crux of this issue is the inability of tumor vaccines to effectively harmonize the tumor microenvironment with its intricate interplay. One factor that can hinder the effectiveness of vaccines is the natural immunosuppressive element present in the tumor microenvironment. This element can lead to low rates of T-cell response specific to antigens and the development of acquired resistance. Conversely, anticancer vaccines alter the tumor microenvironment in conflicting manners, inducing both immune activation and immunological evasion. Hence, comprehending the correlation between tumor vaccines and the tumor microenvironment would establish a foundation for forthcoming tumor treatment. Objective: Our review explores the realm of research pertaining to tumor vaccinations and the tumor microenvironment. Our objective is to investigate the correlation between tumor vaccines and the tumor microenvironment within this domain. We then focus our review on the dominant international paradigms in this research field and visually illustrates the historical progression and emergent patterns observed in the past. Methods: From January 1, 1999 to February 7, 2023, 1420 articles on the interplay between tumor vaccines and the tumor microenvironment were published, according to The Clarivate Web of Science (WOS) database used in our review. A bibliometric review was designed for this collection and consisted of an evaluation. The evaluation encompassed various discernible attributes, including the year of publication, the journals in which the articles were published, the authors involved, the affiliated institutions, the geographical locations of the institutions, the references cited, and the keywords employed. Results: Between the years 1999 and 2022, publications saw a significant increase, from 3 to 265 annually. With 72 papers published, Frontiers in Immunology had the most manuscripts published. The Cancer Research publication garnered the highest number of citations, amounting to 2874 citations. The United States exerts significant dominance in the subject, with the National Cancer Institute being recognized as a prominent institution in terms of both productivity and influence. Furthermore, Elizabeth M. Jaffee was recognized as the field's most prolific and influential author with 24 publications and 1,756 citations. The co-occurrence cluster analysis was conducted on the top 197 keywords, resulting in the identification of five distinct clusters. The most recent high-frequency keywords, namely immune therapy, dendritic cell, tumor microenvironment, cancer, and vaccine, signify the emerging frontiers in the interaction between tumor vaccines and the tumor microenvironment. Conclusion: Our review uncovers insights into contemporary trends, global patterns of collaboration, fundamental knowledge, research areas of high interest, and emerging frontiers in the field of TME-targeted vaccines. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
15. Raising the profile of epidemiological research: discussion paper.
- Author
-
Roth, C. A. and Lenfant, C.
- Subjects
EPIDEMIOLOGICAL research ,BIOMETRY ,MEDICAL research ,CLINICAL trials - Abstract
The article focuses on the role of epidemilogy and biostatistics in the U.S. National Institutes of Health. At the National Heart Lung and Blood Institute, there have been several developments in the field of biomedical. Firstly new knowledge is acquired through basic, applies, clinic research. Then the new knowledge is sanctioned through clinical trials and finally it is transferred to general medical practice by demonstration programmes.
- Published
- 1989
- Full Text
- View/download PDF
16. Rationale, design, and protocol for a hybrid type 1 effectiveness-implementation trial of a proactive smoking cessation electronic visit for scalable delivery via primary care: the E-STOP trial.
- Author
-
Fahey, Margaret C., Wahlquist, Amy E., Diaz, Vanessa A., Player, Marty S., Natale, Noelle, Sterba, Katherine R., Chen, Brian K., Hermes, Eric D. A., Carpenter, Mathew J., and Dahne, Jennifer
- Subjects
EVALUATION of human services programs ,EXPERIMENTAL design ,BIOCHEMISTRY ,SMOKING cessation ,CLINICAL trials ,COUNSELING ,CARBON monoxide ,MOTIVATION (Psychology) ,PHENOMENOLOGICAL biology ,PSYCHOLOGY ,DISEASES ,MEDICAL protocols ,PRIMARY health care ,TREATMENT effectiveness ,HARM reduction ,CONCEPTUAL models ,SMOKING ,ELECTRONIC health records ,MEDICAL appointments ,VARENICLINE ,ALGORITHMS ,TOBACCO - Abstract
Background: Cigarette smoking remains the leading cause of preventable disease and death in the United States. Primary care offers an ideal setting to reach adults who smoke cigarettes and improve uptake of evidence-based cessation treatment. Although U.S. Preventive Services Task Force Guidelines recommend the 5As model (Ask, Advise, Assess, Assist, Arrange) in primary care, there are many barriers to its implementation. Automated, comprehensive, and proactive tools are needed to overcome barriers. Our team developed and preliminarily evaluated a proactive electronic visit (e-visit) delivered via the Electronic Health Record patient portal to facilitate evidence-based smoking cessation treatment uptake in primary care, with promising initial feasibility and efficacy. This paper describes the rationale, design, and protocol for an ongoing Hybrid Type I effectiveness-implementation trial that will simultaneously assess effectiveness of the e-visit intervention for smoking cessation as well as implementation potential across diverse primary care settings. Methods: The primary aim of this remote five-year study is to examine the effectiveness of the e-visit intervention vs. treatment as usual (TAU) for smoking cessation via a clinic-randomized clinical trial. Adults who smoke cigarettes are recruited across 18 primary care clinics. Clinics are stratified based on their number of primary care providers and randomized 2:1 to either e-visit or TAU. An initial baseline e-visit gathers information about patient smoking history and motivation to quit, and a clinical decision support algorithm determines the best evidence-based cessation treatment to prescribe. E-visit recommendations are evaluated by a patient's own provider, and a one-month follow-up e-visit assesses cessation progress. Main outcomes include: (1) cessation treatment utilization (medication, psychosocial cessation counseling), (2) reduction in cigarettes per day, and (3) biochemically verified 7-day point prevalence abstinence (PPA) at six-months. We hypothesize that patients randomized to the e-visit condition will have better cessation outcomes (vs. TAU). A secondary aim evaluates e-visit implementation potential at patient, provider, and organizational levels using a mixed-methods approach. Implementation outcomes include acceptability, adoption, fidelity, implementation cost, penetration, and sustainability. Discussion: This asynchronous, proactive e-visit intervention could provide substantial benefits for patients, providers, and primary care practices and has potential to widely improve reach of evidence-based cessation treatment. Trial registration: NCT05493254. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
17. "Stability Program Management, Clinical Trial Materials: PTC When Using a Contract Stability Lab" - New White Paper from Microtest Laboratories.
- Subjects
CLINICAL trials ,MEDICAL research ,MEDICAL equipment ,PHARMACEUTICAL industry ,CLINICAL medicine - Abstract
The article focuses on the white paper entitled "Stability Program Management, Clinical Trial Materials: PTC When Using a Contract Stability Lab" from the Microtest Laboratories Inc. in the U.S. It states that the paper details the critical issues that need to be addressed by manufacturers of medical equipment and pharmaceutical companies. The paper reviews the development of parenteral stability program for effective stability program management. The authors of the paper are also provided.
- Published
- 2011
18. Simultaneous Global Drug Development and Multiregional Clinical Trials (MRCT): 5 Years After Implementation of ICH E17 Guidelines.
- Author
-
Singh, Rominder, Wang, William, Chakravarty, Aloka, Wang, Jun, and Uyama, Yoshiaki
- Subjects
MEDICAL protocols ,HUMAN services programs ,CLINICAL trials ,INTERNATIONAL agencies ,WORLD health ,RESEARCH ,DRUG development ,STAKEHOLDER analysis ,MEDICAL care costs ,COVID-19 pandemic - Abstract
The ICH E17 guidelines (2014–2017) on Multiregional Clinical Trials (MRCT) was a joint effort by the regulators and industry to facilitate simultaneous global drug development and registration through taking a strategic approach for clinical trials. In other words, the objective was to reduce the time it takes to bringing medications to patients around the world through minimizing unnecessary duplication of local or regional studies, which may add the regulatory burden to cost and time of bringing new therapies to patients. Under the auspices of ICH, training materials were created and provided to various stakeholders. Despite the successful promotion of the benefits of ICH E17 MRCT guidelines across the different regions, the uptake of some concepts (e.g., pooling strategy) in the ICH E17 guidelines has been slow. This paper describes various factors which could affect the conduct of MRCT at a global level, including ambiguity in definition of "region" (in MRCT), new regulatory requirements to enroll a diverse patient population, the use of decentralized clinical trials, use of data sources other than randomized clinical trials (e.g., use of Real Word Data), and the impact of the COVID-19 pandemic on the conduct of MRCT. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
19. The Back Pain Consortium (BACPAC) Research Program: Structure, Research Priorities, and Methods.
- Author
-
Mauck, Matthew C, Lotz, Jeffrey, Psioda, Matthew A, Carey, Timothy S, Clauw, Daniel J, Majumdar, Sharmila, Marras, William S, Vo, Nam, Aylward, Ayleen, Hoffmeyer, Anna, Zheng, Patricia, Ivanova, Anastasia, McCumber, Micah, Carson, Christiane, Anstrom, Kevin J, Bowden, Anton E, Dalton, Diane, Derr, Leslie, Dufour, Jonathan, and Fields, Aaron J
- Subjects
- *
CHRONIC pain , *LUMBAR pain , *PRIORITY (Philosophy) , *ORGANIZATIONAL structure , *WEARABLE technology , *MEDICAL technology , *HUMAN services programs , *ORGANIZATIONAL goals , *CONSORTIA , *OPIOID analgesics , *MEDICAL practice , *MEDICAL research ,RESEARCH evaluation - Abstract
In 2019, the National Health Interview survey found that nearly 59% of adults reported pain some, most, or every day in the past 3 months, with 39% reporting back pain, making back pain the most prevalent source of pain, and a significant issue among adults. Often, identifying a direct, treatable cause for back pain is challenging, especially as it is often attributed to complex, multifaceted issues involving biological, psychological, and social components. Due to the difficulty in treating the true cause of chronic low back pain (cLBP), an over-reliance on opioid pain medications among cLBP patients has developed, which is associated with increased prevalence of opioid use disorder and increased risk of death. To combat the rise of opioid-related deaths, the National Institutes of Health (NIH) initiated the Helping to End Addiction Long-TermSM (HEAL) initiative, whose goal is to address the causes and treatment of opioid use disorder while also seeking to better understand, diagnose, and treat chronic pain. The NIH Back Pain Consortium (BACPAC) Research Program, a network of 14 funded entities, was launched as a part of the HEAL initiative to help address limitations surrounding the diagnosis and treatment of cLBP. This paper provides an overview of the BACPAC research program's goals and overall structure, and describes the harmonization efforts across the consortium, define its research agenda, and develop a collaborative project which utilizes the strengths of the network. The purpose of this paper is to serve as a blueprint for other consortia tasked with the advancement of pain related science. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
20. Leveraging Patient Preference Information in Medical Device Clinical Trial Design.
- Author
-
Rincon-Gonzalez, Liliana, Selig, Wendy K. D., Hauber, Brett, Reed, Shelby D., Tarver, Michelle E., Chaudhuri, Shomesh E., Lo, Andrew W., Bruhn-Ding, Dean, and Liden, Barry
- Subjects
EXPERIMENTAL design ,CLINICAL trials ,STAKEHOLDER analysis ,INSTITUTIONAL review boards ,PATIENTS' attitudes ,CONCEPTUAL structures ,DECISION making ,NEW product development ,STATISTICAL models ,DECISION making in clinical medicine ,PROBABILITY theory - Abstract
Use of robust, quantitative tools to measure patient perspectives within product development and regulatory review processes offers the opportunity for medical device researchers, regulators, and other stakeholders to evaluate what matters most to patients and support the development of products that can best meet patient needs. The medical device innovation consortium (MDIC) undertook a series of projects, including multiple case studies and expert consultations, to identify approaches for utilizing patient preference information (PPI) to inform clinical trial design in the US regulatory context. Based on these activities, this paper offers a cogent review of considerations and opportunities for researchers seeking to leverage PPI within their clinical trial development programs and highlights future directions to enhance this field. This paper also discusses various approaches for maximizing stakeholder engagement in the process of incorporating PPI into the study design, including identifying novel endpoints and statistical considerations, crosswalking between attributes and endpoints, and applying findings to the population under study. These strategies can help researchers ensure that clinical trials are designed to generate evidence that is useful to decision makers and captures what matters most to patients. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
21. Recognize & Resist: An Online Health Intervention to Promote Writing About Sexual Consent and Egalitarian Gender Roles Among One Direction Fanfiction Writers.
- Author
-
McKenzie, Ashley Hedrick, Friedman, Barbara G., Dillman Carpentier, Francesca R., Lazard, Allison J., Salazar, Laura F., and Shegog, Ross
- Subjects
- *
GENDER role , *SEX crimes , *FOCUS groups , *RESEARCH funding , *MEDICAL care , *HUMAN sexuality , *EDUCATIONAL outcomes , *PILOT projects , *INTERVIEWING , *STATISTICAL sampling , *CLINICAL trials , *INTERNET , *SOCIAL norms , *DESCRIPTIVE statistics , *DISEASE prevalence , *SEX customs , *THEMATIC analysis , *RESEARCH methodology , *HEALTH promotion , *WRITTEN communication , *LITERATURE - Abstract
This paper focuses on the development and feasibility of a digitally-based educational intervention, titled Recognize & Resist (R&R), for writers of One Direction (1D) fanfiction on Wattpad.com. The goal of R&R is to reduce the prevalence of social norms that are supportive of sexual violence within 1D fanfiction. 1D fanfictions, or fictional romance stories written by fans of this British boy band, have hundreds of millions of views on Wattpad.com. Formative research has found that social norms supportive of sexual violence are prevalent in 1D fanfictions and that some authors have internalized these norms. R&R aims to motivate 1D fanfiction writers to highlight sexual consent and egalitarian gender roles in their writing. To evaluate the intervention’s feasibility, 15 1D fanfiction authors completed a survey and participated in an interview or focus group. Results demonstrate R&R’s feasibility, with high ratings of its acceptability and demand. Insights from the interviews and focus groups provide suggestions for revising R&R before rigorously evaluating its efficacy. Additionally, results demonstrate the utility of using popular culture as a vehicle for attitude-change regarding sensitive health issues. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
22. Innovative Paperless Clinical Trial Study White Paper Now Available.
- Subjects
ELECTRONIC records ,CLOUD computing ,DIGITAL technology ,CLINICAL trials - Abstract
The article reports on the cloud-based, paperless clinical trial study conducted by researchers at the U.S. National Cancer Institute's Cancer Therapy Evaluation Program (NCI/CTEP), Bristol-Myers Squibb Co. and Sanofi-Aventis SA, which is available at http://www.safe-biopharma.org/whitepaperform.htm. The study uses interoperable digital identities, signatures, and cloud computing for electronic documents. Findings show that digital storage of documents can improve access to clinical resources.
- Published
- 2011
23. The Upfront Cost Hurdle of EDC.
- Author
-
Neuer, Ann, Warnock, Neil, and Slezinger, Edward
- Subjects
ELECTRONIC data processing ,RESEARCH methodology ,CLINICAL trials ,MEDICAL electronics ,DATA quality - Abstract
The article focuses on the significant use of electronic data capture (EDC) in the U.S. It notes that EDC enables researchers in establishing data efficiencies to the clinical trials process. It cites a survey which revealed that the use of EDC brings an estimated 50% acceptance rate. It concludes that in obtaining changes to EDC, it requires important company-wide commitment.
- Published
- 2010
24. Interventions to reduce bruxism in children and adolescents: a systematic scoping review and critical reflection.
- Author
-
Chisini, Luiz Alexandre, San Martin, Alissa Schmidt, Cademartori, Mariana Gonzales, Boscato, Noéli, Correa, Marcos Britto, and Goettems, Marília Leão
- Subjects
BRUXISM ,CRITICAL thinking ,META-analysis ,MASTICATORY muscles ,TEENAGERS ,LEMON balm ,TRAZODONE ,FLURAZEPAM ,CLINICAL trials ,ORTHODONTIC appliances ,AGE distribution ,SYSTEMATIC reviews ,PATIENT satisfaction ,TREATMENT effectiveness ,RISK assessment ,SEVERITY of illness index ,SEX distribution - Abstract
The aim of the present study was to perform a critical reflection about intervention options for bruxism reduction in children and adolescents. Search was conducted based on the PICO-structured question: "What are the intervention options to reduce bruxism in children/adolescents?". No language, year, or study design restrictions were imposed. Studies reporting interventions to reduce bruxism in children (< 10) and adolescents (10 to 19 years old) were included. Reviews and letters to editors were not included. From 2723 records, 17 papers were included. Included studies were primarily randomized clinical trials performed in Brazil (35.3%) and using different criteria for the diagnosis of bruxism. Reduction in self-reported bruxism and headaches associated with bruxism were observed in studies that used medications (hydroxyzine/trazodone/flurazepam), occlusal splints, orthodontic interventions, and psychological and physical therapy interventions. Reduction in Rhythmic Masticatory Muscle Activity was observed with the use of the occlusal splint and in orthodontic interventions. Alternative treatments (medicinal extracts such as Melissa officinalis-L) have shown inconclusive results.Conclusions: Several intervention options are available to inhibit or reduce bruxism activity. The respective indication, contraindications, and side effects of each treatment option must be assessed individually and carefully, taking into account that bruxism is not considered a disorder in otherwise healthy individuals.What is known• Biological and psychological factors have been strongly correlated to the development of bruxism• Bruxism prevalence ranging from 6 to 50% in childrenWhat is new• Reduction in self-reported bruxism and headaches associated with bruxism were observed in studies that used medication (Hydroxyzine/ Trazodone/ Flurazepam), occlusal splints, orthodontic interventions, psychological, and physical therapy interventions• A reduction in Rhythmic Masticatory Muscle Activity was observed with the use of the occlusal splint and orthodontic interventions. Alternative treatments (medicinal extracts such as Melissa officinalis L) show inconclusive results in respect of the reduction in bruxism. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
25. Digital Health Technologies in Clinical Trials: An Ontology-Driven Analysis to Inform Digital Sustainability Policies.
- Author
-
Hey, Spencer Phillips, Dellapina, Maria, Lindquist, Kristin, Hartog, Bert, and LaRoche, Jason
- Subjects
HEALTH policy ,SUSTAINABILITY ,CLINICAL trials ,DIGITAL technology ,BLOOD sugar monitoring ,DIGITAL health ,ACQUISITION of data ,PRIVATE sector ,WEARABLE technology ,WASTE products ,MEDICAL records ,PUBLIC sector ,ONTOLOGIES (Information retrieval) ,CLINICAL trial registries - Abstract
Background: Digital health technologies (DHTs) can facilitate the execution of de-centralized trials that can offer opportunities to reduce the burden on participants, collect outcome data in a real-world setting, and potentially make trial populations more diverse and inclusive. However, DHTs can also be a significant source of electronic waste (e-waste). In recognition of the potential health and environmental impact from DHT use in trials, private and public institutions have recently launched initiatives to help measure and manage this e-waste. But in order to develop sound e-waste management policies, it will be necessary to first estimate the current volume of e-waste that results from the use of DHTs in trials. Materials and Methods: A Web Ontology Language (OWL)-compliant ontology of DHTs was created using a list of 500 DHT device names derived from a mixture of public and private sources. The U.S. clinical trials registry, ClinicalTrials.gov, was then queried to identify and classify trials using any of the devices in the ontology. The ClinicalTrials.gov records from this search were then analyzed to characterize the volume and properties of trials using DHTs, as well as estimating the total volume of individual DHT units that have been provisioned (or are planned to be provisioned) for clinical research. Results: Our ontology-driven search identified 2326 unique clinical trials with a reported "actual" enrollment of 200,947 participants and a "planned" enrollment of an additional 4,094,748 participants. The most-used class of DHTs in our ontology was "wearables," (1852 trials), largely driven by the use of smart watches and other wrist-worn sensors (estimated to involve 149,391 provisioned devices). The most-used subtype of DHTs in trials was "subcutaneous" devices (367 trials), driven by the prevalent use and testing of glucose monitors (estimated to involve 17,666 provisioned devices). Conclusion: Thousands of trials, involving hundreds of thousands of devices, have already been completed, and many more trials (potentially involving millions more devices) are planned. Despite the great opportunities that are afforded by DHTs to the clinical trial enterprise, if the industry lacks the ability to track DHT use with sufficient resolution, the result is likely to be a great deal of e-waste. A new ontology of DHTs, combined with rigorous data science methods like those described in this paper, can be used to provide better information across the industry, and in turn, help create a more sustainable and equitable clinical trials enterprise. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
26. Disparities in breast cancer among patients with disabilities: care gaps, accessibility, and best practices.
- Author
-
Keegan, Grace, Rizzo, John-Ross, and Joseph, Kathie-Ann
- Subjects
- *
PEOPLE with disabilities , *MEDICAL personnel , *BREAST cancer , *CARE of people with disabilities , *CANCER patients , *CLINICAL trials - Abstract
Pronounced disparities exist in detecting and treating breast cancer in women with disabilities, leading to cancer detection at advanced stages. This paper provides an overview of disparities for women with disabilities related to breast cancer screening and care, primarily focusing on clinically significant mobility disabilities. Current care gaps include screening barriers related to accessibility and inequitable treatment options, with race and ethnicity, socioeconomic status, geographic location, and disability severity factors mediating the disparities for this population. The reasons for these disparities are myriad and stem from both system-level deficiencies and individual-level clinician bias. Although structural changes are warranted, individual healthcare professionals must also be incorporated into the requisite change. Intersectionality is critical to disparities and inequities and should be central to any discussion of strategies for improving care for people with disabilities, many of whom have intersectional identities. Efforts to reduce screening rate disparities for breast cancer in women with mobility-related disabilities should start with improving accessibility through removing structural barriers, establishing comprehensive accessibility standards, and addressing healthcare professional bias. Future interventional studies are needed to implement and assess the value of programs to improve breast cancer screening rates in women with disabilities. Increasing the representation of women with disabilities in clinical trials may provide another avenue for reducing treatment disparities because these trials often provide breakthrough treatment to women with cancer diagnosed at later stages. Ultimately, attention to the specific needs of patients with disabilities should be improved across the United States to promote inclusive and effective cancer screening and treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
27. Innovation in Ethical Review.
- Author
-
Sodrel, Jennifer
- Subjects
INSTITUTIONAL review boards ,MEDICAL research ,MEDICAL protocols ,RECORDS management ,MEDICAL experimentation on humans ,CLINICAL trials - Abstract
The article discusses the innovation of guidelines which serves as reference of Institutional Review Boards (IRB) in conducting ethical reviews on protocols for clinical research in the U.S. Food and Drug Administration (FDA) has assigned IRB to review medical protocols in which the primary responsibility is to ensure the safety of human participants in the research. It notes on the change to electronic paperless management to share and collaborate documents for the clinical trials.
- Published
- 2011
28. The Power of the Web in Cancer Drug Discovery and Clinical Trial Design: Research without a Laboratory?
- Author
-
Galustian, Christine and Dalgleish, Angus G.
- Subjects
CANCER treatment ,CLINICAL trials ,DATA mining - Abstract
The discovery of effective cancer treatments is a key goal for pharmaceutical companies. However, the current costs of bringing a cancer drug to the market in the USA is now estimated at $1 billion per FDA approved drug, with many months of research at the bench and costly clinical trials. A growing number of papers highlight the use of data mining tools to determine associations between drugs, genes or protein targets, and possible mechanism of actions or therapeutic efficacy which could be harnessed to provide information that can refine or direct new clinical cancer studies and lower costs. This report reviews the paper by R.J. Epstein, which illustrates the potential of text mining using Boolean parameters in cancer drug discovery, and other studies which use alternative data mining approaches to aid cancer research. [ABSTRACT FROM AUTHOR]
- Published
- 2010
29. The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trials.
- Author
-
Marchetti, S and Schellens, J H M
- Subjects
DRUG development ,PHARMACOLOGY ,MEDICAL research ,CANCER treatment ,INDUSTRIAL laws & legislation ,DRUG approval laws ,GOVERNMENT agencies ,CLINICAL trials ,INDUSTRIES ,MEDICAL protocols ,DRUG approval - Abstract
An increase in the number of identified therapeutic cancer targets achieved through recent biomedical research has resulted in the generation of a large number of molecules that need to be tested further. Current development of (anticancer) drugs is a rather inefficient process that for an average new molecule takes around 10–15 years. It is also a challenging process as it is associated with high costs and a low rate of approval. It is known that less than 10% of new molecular entities entering clinical Phase I testing progress beyond the investigational programme and reach the market; this probability is even lower for anticancer agents. In 2003, the US Food and Drug Administration (US FDA) declared the urgent need for new toolkits to improve the critical development path that leads from scientific discovery to the patient. In this scenario, Phase 0 (zero) trials should allow an early evaluation in humans of pharmacokinetic and pharmacodynamic profiles of test compounds through administration of sub-pharmacological doses and for a short time period to a low number of humans. Typically, Phase 0 studies have no therapeutic or diagnostic intent. Owing to the low doses administered and the low risk of toxicity, shorter preclinical packages to support these studies are required. Phase 0 trials have been proposed to help in making an early selection of promising candidates for further evaluation in Phase I–III trials, providing a potentially useful instrument for drug discovery, particularly in the field of oncology. Phase 0 studies are expected to reduce costs of drug development, and to limit the preclinical in vitro and in vivo testing and the time period of drug development. However, there are also concerns about the utility and feasibility of Phase 0 studies. In January 2006, guidelines on exploratory investigational new drug studies in humans have been published by the US FDA, and currently a Phase 0 programme is ongoing at the National Cancer Institute to evaluate the impact (feasibility and utility) of Phase 0 studies on drug development. In Europe, a Position Paper produced by the Evaluation of Medicinal Products (EMEA) in 2004 raised the possibility of a reduced preclinical safety package to support early microdose clinical studies, and, as announced by a recent Concept Paper on medicinal products published by the committee for medicinal products for human use of the EMEA, EMEA's guidelines on Phase 0 studies are expected shortly. The true impact of Phase 0 studies on the drug development process as well as on the safety needs to be carefully explored.British Journal of Cancer (2007) 97, 577–581. doi:10.1038/sj.bjc.6603925 www.bjcancer.com Published online 28 August 2007 [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
30. Considerations for designing and implementing combination HIV cure trials: findings from a qualitative in-depth interview study in the United States.
- Author
-
Dubé, Karine, Kanazawa, John, Dee, Lynda, Taylor, Jeff, Sauceda, John A., Gianella, Sara, Smith, Davey, Deeks, Steven G., and Peluso, Michael J.
- Subjects
EXPERIMENTAL design ,HIV infections ,CLINICAL trials ,COMBINATION drug therapy ,IMMUNOGLOBULINS ,RESEARCH methodology ,STAKEHOLDER analysis ,PSYCHOLOGY of human research subjects ,ANTIRETROVIRAL agents ,QUALITATIVE research ,JUDGMENT sampling ,CONTENT analysis ,THEMATIC analysis - Abstract
Background: An increasing number of HIV cure trials involve combining multiple potentially curative interventions. Until now, considerations for designing and implementing complex combination HIV cure trials have not been thoroughly considered. Methods: We used a purposive method to select key informants for our study. Informants included biomedical HIV cure researchers, regulators, policy makers, bioethicists, and community members. We used in-depth interviews to generate ethical and practical considerations to guide the design and implementation of combination HIV cure research. We analyzed the qualitative data using conventional content analysis focused on inductive reasoning. Results: We interviewed 11 biomedical researchers, 4 community members, 2 regulators, 1 policy researcher, and 1 bioethicist. Informants generated considerations for designing and implementing combination interventions towards an HIV cure, focused on ethical aspects, as well as considerations to guide trial design, benefit/risk determinations, regulatory requirements, prioritization and sequencing and timing of interventions, among others. Informants also provided considerations related to combining specific HIV cure research modalities, such as broadly neutralizing antibodies (bNAbs), cell and gene modification products, latency-reversing agents and immune-based interventions. Finally, informants provided suggestions to ensure meaningful therapeutic improvements over standard antiretroviral therapy, overcome challenges of designing combination approaches, and engage communities around combination HIV cure research. Conclusion: The increasing number of combination HIV cure trials brings with them a host of ethical and practical challenges. We hope our paper will inform meaningful stakeholder dialogue around the use of combinatorial HIV cure research approaches. To protect the public trust in HIV cure research, considerations should be periodically revisited and updated with key stakeholder input as the science continues to advance. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
31. Medical Research for Hire: Gender and the Privatization of Clinical Trials.
- Author
-
Fisher, Jill A.
- Subjects
MEDICAL research ,CLINICAL trials ,PRIVATIZATION ,MEDICINE ,PHARMACEUTICAL industry - Abstract
This paper will focus on emerging cultures of clinical trials by analyzing the relationships that are produced between physicians and their research staff and between research staff and patients who volunteer for studies. Central to this analysis will be attention to the production of gender relationships within the clinical trials industry, particularly in terms of two conceptual threads: idiocy and altruism. Drawing upon fieldwork in the southwestern United States, this paper will explore how these themes surface in the narratives of physicians and research staff. These informant narratives will dramatize the ways in which patriarchy and medical paternalism continue to thrive, but also have changed, within new manifestations of medical and pharmaceutical cultures. Moreover, this examination of gender and the clinical trials industry demonstrates that power operates simultaneously through organizational structures ? institutional power ? and through individuals ? biopower. [ABSTRACT FROM AUTHOR]
- Published
- 2005
32. The impact of health insurance mandates on drug innovation: evidence from the United States.
- Author
-
Chun, Natalie and Park, Minjung
- Subjects
HEALTH insurance ,GOVERNMENT policy ,CLINICAL trials ,MEDICAL research ,INSURANCE - Abstract
An important health policy issue is the low rate of patient enrollment into clinical trials, which may slow down the process of clinical trials and discourage their supply, leading to delays in innovative life-saving drug treatments reaching the general population. In the US, patients' cost of participating in a clinical trial is considered to be a major barrier to patient enrollment. In order to reduce this barrier, some states in the US have implemented policies requiring health insurers to cover routine care costs for patients enrolled in clinical trials. This paper evaluates empirically how effective these policies were in increasing the supply of clinical trials and speeding up their completion, using data on cancer clinical trials initiated in the US between 2001 and 2007. Our analysis indicates that the policies did not lead to an increased supply in the number of clinical trials conducted in mandate states compared to non-mandate states. However, we find some evidence that once clinical trials are initiated, they are more likely to finish their patient recruitment in a timely manner in mandate states than in non-mandate states. As a result, the overall length to completion was significantly shorter in mandate states than in non-mandate states for cancer clinical trials in certain phases. The findings hint at the possibility that these policies might encourage drug innovation in the long run. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
33. Deploying Mobile Devices in Clinical Trials.
- Author
-
El Emam, Khaled
- Subjects
CLINICAL trials ,ELECTRONIC data processing ,ELECTRONIC data interchange ,MEDICAL research ,MOBILE communication systems ,COMPUTER software - Abstract
The article reports on the adoption of electronic data capture (EDC) systems in clinical trials in the U.S. The adoption of EDC has increased in the country because of its potential benefits such as the efficient monitoring, rapid access to trial data, higher quality of data, reduced queries and instantaneous alert. EDC system with mobile technology could reduce the reliance on paper and streamline the workforce.
- Published
- 2006
34. Brief educational video plus telecare to enhance recovery for older emergency department patients with acute musculoskeletal pain: study protocol for the BETTER randomized controlled trial.
- Author
-
Platts-Mills, Timothy F., McLean, Samuel A., Weinberger, Morris, Stearns, Sally C., Bush, Montika, Teresi, Brittni B., Hurka-Richardson, Karen, Kroenke, Kurt, Kerns, Robert D., Weaver, Mark A., and Keefe, Francis J.
- Subjects
EDUCATIONAL films ,RANDOMIZED controlled trials ,HOSPITAL emergency services ,OLDER people ,CHRONIC pain ,POSTOPERATIVE pain ,MEDICAL communication ,RESEARCH ,PAIN measurement ,CLINICAL trials ,OUTPATIENT medical care ,TIME ,ANALGESICS ,TELEPHONES ,MEDICAL cooperation ,TREATMENT effectiveness ,RESEARCH funding ,PATIENT education ,TELEMEDICINE ,VIDEO recording - Abstract
Background: Chronic musculoskeletal pain (MSP) affects more than 40% of adults aged 50 years and older and is the leading cause of disability in the USA. Older adults with chronic MSP are at risk for analgesic-related side effects, long-term opioid use, and functional decline. Recognizing the burden of chronic MSP, reducing the transition from acute to chronic pain is a public health priority. In this paper, we report the protocol for the Brief EducaTional Tool to Enhance Recovery (BETTER) trial. This trial compares two versions of an intervention to usual care for preventing the transition from acute to chronic MSP among older adults in the emergency department (ED).Methods: Three hundred sixty patients from the ED will be randomized to one of three arms: full intervention (an interactive educational video about pain medications and recovery-promoting behaviors, a telecare phone call from a nurse 48 to 72 h after discharge from the ED, and an electronic communication containing clinical information to the patient's primary care provider); video-only intervention (the interactive educational video but no telecare or primary care provider communication); or usual care. Data collection will occur at baseline and at 1 week and 1, 3, 6, and 12 months after study enrollment. The primary outcome is a composite measure of pain severity and interference. Secondary outcomes include physical function, overall health, opioid use, healthcare utilization, and an assessment of the economic value of the intervention.Discussion: This trial is the first patient-facing ED-based intervention aimed at helping older adults to better manage their MSP and reduce their risk of developing chronic pain. If effective, future studies will examine the effectiveness of implementation strategies.Trial Registration: ClinicalTrials.gov NCT04118595 . Registered on 8 October 2019. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
35. Fluoropyrimidine-induced toxicity and DPD deficiency.. A case report of early onset, lethal capecitabine-induced toxicity and mini review of the literature. Uridine triacetate: Efficacy and safety as an antidote. Is it accessible outside USA?
- Author
-
Lampropoulou, Dimitra Ioanna, Laschos, Konstantinos, Amylidi, Anna-Lea, Angelaki, Ariadni, Soupos, Nikolaos, Boumpoucheropoulos, Sotirios, Papadopoulou, Eirini, Nanou, Evgenia, Zidianakis, Vasilios, Nasioulas, George, Fildissis, George, and Aravantinos, Gerasimos
- Subjects
ANTIDOTES ,ANTIMETABOLITES ,CANCER chemotherapy ,CLINICAL trials ,COLON tumors ,DRUG toxicity ,GENETIC polymorphisms ,METABOLISM ,INBORN errors of metabolism ,MOLECULAR structure ,NUCLEOSIDES ,RECTUM tumors ,TREATMENT effectiveness ,EARLY diagnosis - Abstract
Fluoropyrimidine-based regimens are among the most commonly used chemotherapy combinations for the treatment of solid tumors. Several genetic polymorphisms that are implicated with fluoropyrimidine anabolism and catabolism have been associated with the development of life-threatening toxicities. Uridine triacetate is an FDA-approved antidote for 5-fluorouracil or capecitabine overdose and early-onset, life-threatening toxicity within 96 h of last chemotherapy dose. To date, it is not accessible for Greek patients as per the current summary of product characteristic's time restrictions. We report and discuss the course and outcome of capecitabine toxicity in a 66-year-old female colorectal cancer patient with heterozygous dihydropyrimidine dehydrogenase deficiency. This paper highlights the difficulty in timely access of this lifesaving medication for Greek and possibly other European patients. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
36. When ignorance is bliss: Intentional agnosticism in drug approval.
- Author
-
Litvin, Valentyn
- Subjects
DRUG approval ,HEALTH policy ,CLINICAL trials ,PATIENT selection ,AGE distribution ,MEDICAL prescriptions - Abstract
In developed nations, public health agencies typically use data from randomized controlled trials to evaluate new drugs. However, these trials routinely exclude populations to which clinicians prescribe approved drugs, meaning some patients are treated with drugs, which were approved on the basis of another group's treatment response. Despite having opportunities to change, some health agencies have not mandated greater inclusion in drug trials and appear to prefer remaining ignorant of some populations' treatment effects when approving a drug. To explore this decision, I introduce a novel mechanism by which a health agency would choose to be intentionally agnostic regarding a population's treatment response. The main contribution of this paper is in showing how ambiguity about on-label and off-label prescription rates could possibly encourage population exclusion in drug approval trials even in the absence of concerns about trial necessity or cost. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
37. How prominent are patient-reported outcomes in clinical trials of dermatological treatments?
- Author
-
Townshend, A.P., Chen, C-M., and Williams, H.C.
- Subjects
SKIN diseases ,CLINICAL trials ,MEDICINE ,DERMATOLOGY ,MEDICAL research - Abstract
Background Assessment of symptoms or disease improvement by study participants is an important aspect of assessing new dermatological therapies in clinical trials, especially for chronic skin diseases that lack objective severity markers. Objectives We sought to determine the frequency and prominence of reporting of participants’ subjective efficacy outcomes in dermatological clinical trials. Our secondary objective was to determine whether participant and physician outcomes agree in terms of direction and magnitude. Methods Systematic review of 125 randomized controlled trials identified from the Archives of Dermatology, British Journal of Dermatology, Clinical & Experimental Dermatology, Journal of Dermatological Treatment and Journal of the American Academy of Dermatology published between 1994 and 2001 (25 from each). Studies were retrieved in hard copy from the Cochrane Skin Group specialized register of trials and data were abstracted and summarized. Results Participant efficacy outcomes were mentioned in some form in only 32 of 125 trials (25·6%, 95% exact confidence interval 18·2–34·2%). Of these 32 studies, participant outcomes were mentioned only in the methods section in two studies, in the methods and results section without further data in nine studies and with further data in 21. Data were presented in figure format only in 12 of these studies and in tables and figures in nine. Participant efficacy outcomes were mentioned in the abstract section in just over half (53%) of the 32 trials that included participant efficacy outcomes. There was not enough information to assess agreement in direction and magnitude of participant vs. assessor outcomes. Overall, only 17 papers (13·6%) clearly declared their main outcome measures beforehand in the introduction or methods section. Conclusions Asking study participants for their views of treatment efficacy seems like a good idea in dermatological clinical trials, yet only about a quarter of the trials examined in this review did so. Even when such information was recorded, it was often poorly and incompletely reported and given low prominence within the trial report. Our study findings call for a more comprehensive uptake for including participant efficacy outcomes alongside other assessor outcomes in clinical trials and, when included, to report those outcomes in full. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
38. The State of E-clinical Technology.
- Author
-
Cline, John
- Subjects
MEDICAL innovations ,MEDICAL technology ,CLINICAL trials ,DRUG development - Abstract
The article focuses on the use of electronic data capture (EDC) and other electronic clinical solution in clinical trials. Clinical trial sponsors are considering these innovations as integral part in clinical trials, since they are more efficient, more sensible and safe means of reporting results. It is expected that electronic clinical solutions will take on an even stronger role in drug development as the U.S. Food and Drug Administration and other regulators lend their approval.
- Published
- 2007
39. Grasping the FDA's PRO Guidance.
- Author
-
Shields, Alan, Gwaltney, Chad, Tiplady, Brian, Paty, Jean, and Shiffman, Saul
- Subjects
CLINICAL trials ,MEDICAL research ,PATIENTS ,MEDICAL equipment - Abstract
The article provides some insights into the implementation of the United States Food and Drug Administration's (FDA) patient reported outcome (PRO) which provide data directly from patient self-reports. The FDA's PRO Guidance has been issued to describe how patients will evaluate PRO instruments, and lays out the type and quality of information that clinical researchers will need to provide to justify the use of a particular PRO instrument in a trial.
- Published
- 2006
40. Multicentre trials: a US regulatory perspective.
- Author
-
Anello, Charles, O'Neill, Robert T, and Dubey, Satya
- Subjects
CLINICAL trials ,MEDICAL research ,TRADE regulation ,DRUG development ,PHARMACY ,DRUG metabolism - Abstract
Multicentre trials are very common in the field of drug development. In recent years, multicentre trials have taken on a multinational and multiregional aspect. We provide a conceptual framework for the use of multicentre trials in the context of drug development, from the perspective of drug regulation in the United States. In this paper, we review some regulatory history, milestones and standards as they relate to multicentre trials. Special attention is given to the similarities and differences in the approaches to multicentre trials in the following documents; Guideline for the Format and Content of the Clinical and Statistical Sections of New Drug Applications, International Conference on Harmonization, Draft Guideline on Statistical Principles for clinical trials and the Guidance for Industry Providing Clinical Evidence of Effectiveness for Human Drug and Biologic Products. The paper includes a consideration of some of the issues in the analysis of data from multicentre trials. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
41. Trade-Offs in the Conduct of Economic Evaluations of Child Mental Health Services.
- Author
-
Edwards, Rhiannon Tudor and Thalanany, Mariamma
- Subjects
CONJOINT analysis ,ECONOMICS ,CHILD mental health services ,CHILDHOOD Autism Rating Scale ,CHILDREN'S health ,CLINICAL trials - Abstract
Childhood psychological morbidity places both short-term and long-term costs on families, health services, social services, voluntary organizations, and society as a whole. Internationally, there have been few economic evaluations alongside clinical trials of population-based interventions to improve child mental well-being. This paper sets out a number of trade-offs relevant to the evaluation of the costs and benefits of multisectoral interventions to improve child mental well-being. These trade-offs have relevance for those who fund research, those who conduct research, and those who make policy decisions. The paper sets out a conceptual model for the economic evaluation of population-based interventions to improve child mental health. Finally, the paper argues that with the advent of “joined up” public policy and the breakdown of traditional ring-fenced budgets for health and social care, there is now, more than ever before, an opportunity for the research community to generate guidance for multisectoral collaborative interventions to promote the mental well-being of children and their families. [ABSTRACT FROM AUTHOR]
- Published
- 2001
- Full Text
- View/download PDF
42. Twenty years and still counting: including women as participants and studying sex and gender in biomedical research.
- Author
-
Mazure, Carolyn M. and Jones, Daniel P.
- Subjects
MEDICAL research ,CLINICAL trials ,PUBLIC health ,HEALTH outcome assessment ,INTERPERSONAL relations ,RESEARCH funding ,PATIENT selection - Abstract
Background: This paper chronicles attempts in the United States over the past 20 years to fully represent women in clinical trials and ensure the study of sex and gender in biomedical research. We maintain that productive science with the aim of serving the public health requires examining the influence of sex and gender on health outcomes.Discussion: This section provides a historical perspective on the changes in recommendations and requirements of both the National Institutes of Health - the world's largest single funder of biomedical research - and the U.S. Food and Drug Administration - the world's most influential regulator of drugs and medical devices - for the acceptable conduct of research as it relates to sex and gender. We also cite all reports by the U.S. Institute of Medicine and the U.S. Congress' General Accountability Office issued from 1990 to the present on the inclusion of sex and gender in research, and selected high-impact published studies that illustrate and document the paucity of, yet the need for, inclusion of females and consideration of sex and gender in research across an array of biomedical disciplines. The key message of this paper is that it has been 20 years since the first requirements to include women as well as men in clinical trials and analyze results by sex were mandated by a U.S. federal law, yet not nearly enough progress has been made. Recent signs of potential change in both policy and practice of scientific inquiry suggest much more progress may be within reach. However, awaiting a cultural shift to allow the study of sex and gender to be embraced is not seen as an effective strategy for change. Rather, specific instrumental recommendations are offered for how to include the study of sex and gender in research so as to increase our understanding and promotion of health for the benefit of all. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
43. A Mini-Review of Strategies for Recruiting Older African Americans to Alzheimer's Disease Research.
- Author
-
Esiaka, Darlingtina, Yarborough, Christina C., Fausto, Bernadette A., and Gluck, Mark A.
- Subjects
PATIENT selection ,COMMUNITY health services ,ALZHEIMER'S disease ,AFRICAN Americans ,INTERPROFESSIONAL relations ,HUMAN research subjects ,PUBLIC relations ,TELEMEDICINE ,AGING ,COMMUNICATION ,HEALTH promotion ,MEDICAL referrals - Abstract
African Americans experience higher incidence and prevalence of Alzheimer's disease (AD). Yet, they continue to be underrepresented in AD research, limiting the ability to generalize findings to the increasingly diverse US population. To reduce AD disparities, targeted efforts are needed to increase the representation of African Americans in AD research. This mini review identified evidence-based strategies that increased research participation among older African Americans. Four recruitment strategies emerged from eight published peer-reviewed studies that directly evaluated the effectiveness of strategies aimed at increasing the number of African American participants in Alzheimer's research. The strategies include community outreach and education, face-to-face discussions, remote access, and referral and partnership with local organizations. Across different locations, these strategies increased the number of African Americans enrolled into AD research, the number of people that signed up to donate their brains for AD research upon death, and the knowledge and perception of AD in the communities. Targeted efforts are effective in increasing AD research participation among older African Americans, especially when combined with approaches that emphasize transparency and mutual trust and involve the community as stakeholders in the research process. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
44. A new era in the management of Duchenne muscular dystrophy.
- Author
-
Korinthenberg, Rudolf
- Subjects
DUCHENNE muscular dystrophy ,GENETIC code ,DRUG approval ,MANAGEMENT ,LITERATURE reviews ,CLINICAL trials ,TREATMENT of Duchenne muscular dystrophy ,DIAGNOSIS of Duchenne muscular dystrophy ,PSYCHOLOGICAL adjustment testing ,DISEASES ,DYADIC Adjustment Scale - Abstract
Copyright of Developmental Medicine & Child Neurology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2019
- Full Text
- View/download PDF
45. An application architecture to facilitate multi-site clinical trial collaboration in the cloud.
- Author
-
Sharp, Jonathan
- Subjects
MEDICAL care ,ECOLOGY ,CLINICAL trials ,ELECTRONIC systems - Abstract
The regulatory environment in the U.S. healthcare sector and the privacy concerns surrounding personal health information complicate research collaborations between investigators, especially collaborations across healthcare organizational boundaries. This paper examines software systems traditionally employed by healthcare providers to utilize clinical data for research purposes within and between organizations. A conceptual software architecture utilizing cloud-based services is then proposed that, it is suggested, may facilitate collaboration between researchers in multisite clinical trials. Several related challenge areas are then identified. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
46. Framing the Policy Debate: Exploring Advocacy, Science, and Congressional Attention to Women's Health.
- Author
-
Quon, Nicole C.
- Subjects
- *
HEALTH policy , *CLINICAL trials , *HEALTH promotion , *THERAPEUTICS - Abstract
Women's health advocates successfully lobbied for many federal health policy changes in the 1990s, including increased participation in clinical trials, more funding for research and health promotion for important diseases, and improved access to medical treatments. The roles of politicians and advocates in the women's health movement during the last fifteen years are well documented. Less is known, however, about how elite discourse about women's health shapes the policy process. This paper explores the politics of women's health by examining the role of information during Congressional hearings. Does reliance on value-based assessments or expert opinions depend on the type of issue or the type of witness? Do witnesses favor certain types of persuasion when they agree (or disagree) with members of Congress? This study utilizes a new dataset that includes measures of conflict between panelists and members of Congress during hearings, classifications of women's health concerns, and witness characteristics. The findings from this study improve our understanding of how women's health advocates and their allies influence health policy. ..PAT.-Unpublished Manuscript [ABSTRACT FROM AUTHOR]
- Published
- 2008
47. Practicing Research Ethics: Private-Sector Physicians & Pharmaceutical Clinical Trials.
- Author
-
Fisher, Jill A.
- Subjects
RESEARCH ethics ,PHYSICIANS ,CODES of ethics ,PROFESSIONAL ethics ,PHARMACEUTICAL industry - Abstract
This paper focuses on private-sector physicians' constructions of research ethics as they engage in contract research for the pharmaceutical industry. Drawing first upon historical studies of physicians as investigators and then upon current qualitative research, this paper analyzes the shifting, contextualized ethics that shape physicians' relationships with patients/subjects and pharmaceutical companies. Just as physicians followed professional codes of ethics prior to the codification of acceptable research conduct in the 1980s, physicians today continue to develop tacit systems of research ethics. This paper argues that private-sector physicians primarily conceptualize their ethical conduct in relation to the pharmaceutical companies hiring them, not to human subjects they enroll in clinical trials. This is not to say that these physicians do not follow the formal U.S. regulation to protect human subjects, but rather that their financial relationships with the pharmaceutical industry have a greater influence on their identities as researchers and on their perceptions of their ethical responsibilities. ..PAT.-Unpublished Manuscript [ABSTRACT FROM AUTHOR]
- Published
- 2007
48. Involvement of Homeless Individuals in Pharmaceutical Clinical Trials.
- Author
-
Irwin, Sharlotte
- Subjects
LEGAL status of homeless people ,HOMELESS persons ,CLINICAL trials ,PHARMACEUTICAL research - Abstract
In the United States, homeless individuals find themselves vulnerable to many kinds of harm and exploitation, including in relation to pharmaceutical research. This paper begins by identifying the characteristics that make a person both homeless and vulnerable to research. Then, it explores specific incidences of pharmaceutical researchers using homeless individuals for Phase I clinical trials, a practice which first came to public awareness in the 1990s. Ethical principles are then applied to these scenarios, focusing specifically on undue inducement, structural coercion, exploitation, and unfair exclusion. Finally, possible solutions are presented to help resolve the aforementioned concerns, providing suggestions for both the research world and the socio-political context. [ABSTRACT FROM AUTHOR]
- Published
- 2018
49. Increasing Efficiency of Recruitment in Early Parkinson's Disease Trials: A Case Study Examination of the STEADY-PD III Trial.
- Author
-
Berk, Sarah, Greco, Brittany L., Biglan, Kevin, Kopil, Catherine M., Holloway, Robert G., Meunier, Claire, and Simuni, Tanya
- Subjects
PARKINSON'S disease ,CLINICAL trials ,PUBLIC health ,MEDICAL protocols ,PATIENT participation - Abstract
Background: Challenges in clinical trial recruitment threaten the successful development of improved therapies. This is particularly true in Parkinson's disease (PD) studies of disease modification where the population of interest is difficult to find and study design is more complex. Objective: This paper seeks to understand how STEADY PD III, a National Institute of Neurological Disorders and Stroke (NINDS) funded phase 3 trial evaluating the efficacy of isradipine as a disease modifying agent for PD, was able to recruit their full target population 6 months ahead of schedule. Methods: STEADY PD III aimed to enroll 336 individuals with early stage idiopathic PD within 18 months using 57 sites across the United States and Canada. The study included a 10% NIH minority recruitment goal. Eligible participants agreed to be followed for up to 36 months, complete 12 in-person visits and 4 telephone visits. A Recruitment Committee of key stakeholders was critical in the development of a comprehensive recruitment strategy involving: multi-modal outreach, protocol modifications and comprehensive site selection and activation. Efforts to increase site-specific minority recruitment strategies were encouraged through additional funding. Results:Atotal of 336 individuals, including 34 minorities, were enrolled within 12 months - 6 months ahead of the projected timeline. Quantitative analysis of recruitment activity questionnaires found that of the sites that completed them (n = 54), (20.4%) met goals, (24.1%) exceeded goals, and (55.6%) fell below projected goals. Referral sources completed at time of screening indicate top four study referral sources as: site personnel (53.8%); neurologists (24%); Fox Trial Finder (10.2%); and communications from The Michael J. Fox Foundation (3.9%). Conclusions:STEADYPDIII serves as an important example of methods that can be used to increase clinical trial recruitment. This research highlights a continued need to improve site infrastructure and dedicate more resources to increased participation of minorities in clinical research. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
50. A single-center, assessor-blinded, randomized controlled clinical trial to test the safety and efficacy of a novel brain-computer interface controlled functional electrical stimulation (BCI-FES) intervention for gait rehabilitation in the chronic stroke population
- Author
-
Biswas, Piyashi, Dodakian, Lucy, Wang, Po T., Johnson, Christopher A., See, Jill, Chan, Vicky, Chou, Cathy, Lazouras, Wendy, McKenzie, Alison L., Reinkensmeyer, David J., Nguyen, Danh V., Cramer, Steven C., Do, An H., and Nenadic, Zoran
- Subjects
ELECTRIC stimulation ,BRAIN-computer interfaces ,CLINICAL trials ,STROKE rehabilitation ,NEURAL stimulation ,MEDICAL rehabilitation ,BODY-weight-supported treadmill training - Abstract
Background: In the United States, there are over seven million stroke survivors, with many facing gait impairments due to foot drop. This restricts their community ambulation and hinders functional independence, leading to several long-term health complications. Despite the best available physical therapy, gait function is incompletely recovered, and this occurs mainly during the acute phase post-stroke. Therapeutic options are limited currently. Novel therapies based on neurobiological principles have the potential to lead to long-term functional improvements. The Brain-Computer Interface (BCI) controlled Functional Electrical Stimulation (FES) system is one such strategy. It is based on Hebbian principles and has shown promise in early feasibility studies. The current study describes the BCI-FES clinical trial, which examines the safety and efficacy of this system, compared to conventional physical therapy (PT), to improve gait velocity for those with chronic gait impairment post-stroke. The trial also aims to find other secondary factors that may impact or accompany these improvements and establish the potential of Hebbian-based rehabilitation therapies. Methods: This Phase II clinical trial is a two-arm, randomized, controlled, longitudinal study with 66 stroke participants in the chronic (> 6 months) stage of gait impairment. The participants undergo either BCI-FES paired with PT or dose-matched PT sessions (three times weekly for four weeks). The primary outcome is gait velocity (10-meter walk test), and secondary outcomes include gait endurance, range of motion, strength, sensation, quality of life, and neurophysiological biomarkers. These measures are acquired longitudinally. Discussion: BCI-FES holds promise for gait velocity improvements in stroke patients. This clinical trial will evaluate the safety and efficacy of BCI-FES therapy when compared to dose-matched conventional therapy. The success of this trial will inform the potential utility of a Phase III efficacy trial. Trial registration: The trial was registered as "BCI-FES Therapy for Stroke Rehabilitation" on February 19, 2020, at clinicaltrials.gov with the identifier NCT04279067. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.